Literature DB >> 12019276

Aldosterone is produced from ventricles in patients with essential hypertension.

Nobuyasu Yamamoto1, Hirofumi Yasue, Yuji Mizuno, Michihiro Yoshimura, Hiromi Fujii, Masafumi Nakayama, Eisaku Harada, Shota Nakamura, Teruhiko Ito, Hisao Ogawa.   

Abstract

This study was designed to examine whether aldosterone is produced from the hearts of patients with essential hypertension without left ventricular systolic dysfunction (LVSD). The study population consisted of 20 patients with essential hypertension without LVSD and 22 control subjects. Plasma levels of aldosterone, serum ACE activity, and B-type natriuretic peptide levels were measured in the anterior interventricular vein (AIV), coronary sinus, and aortic root during cardiac catheterization. The plasma aldosterone levels were significantly higher in AIV and coronary sinus than in aortic root (99+/-11 versus 88+/-10 pg/mL, P<0.01, and 100+/-12 versus 88+/-10 pg/mL, P<0.01, respectively) in the hypertension group. On the other hand, there were no significant differences in aldosterone levels for these sites in the control group. There were no significant differences in ACE activity levels between aortic root, AIV, and coronary sinus in either the hypertension or control group. The levels of B-type natriuretic peptide were significantly higher in AIV than in aortic root in both groups. The difference in aldosterone levels between AIV and aortic root (Delta Aldo[AIV-Ao]) had a significant positive correlation with the difference in ACE activity between AIV and aortic root (DeltaACE[AIV-Ao]) (r=0.501, P<0.05) in the hypertension group. Both Delta Aldo[AIV-Ao] and DeltaACE[AIV-Ao] had a significant positive correlation with diastolic blood pressure (r=0.498, P<0.05; r=0.577, P<0.01, respectively) in the hypertension group. We conclude that production of aldosterone is activated in the left ventricles in patients with essential hypertension without LVSD in proportion to the severity of hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019276     DOI: 10.1161/01.hyp.0000015905.27598.e9

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

1.  Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V2 receptor-independent pathway.

Authors:  Yusuf Ali; Kaoru Dohi; Ryuji Okamoto; Kan Katayama; Masaaki Ito
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

2.  Interaction between the heme oxygenase system and aldosterone in hypertension.

Authors:  Joseph Fomusi Ndisang; Ashok Jadhav; Nina Lane
Journal:  Int J Angiol       Date:  2007

3.  Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy.

Authors:  Jessica A Chadwick; Sarah A Swager; Jeovanna Lowe; Steven S Welc; James G Tidball; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Jill A Rafael-Fortney
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

4.  Distribution and phenotypic expression of mineralocorticoid receptor and CYP11B2 T-344C polymorphisms in a Taiwanese hypertensive population.

Authors:  Sung-Kien Sia; Hui-Ling Chiou; Shiuan-Chih Chen; Chin-Feng Tsai; Shun-Fa Yang; Kwo-Chang Ueng
Journal:  Mol Biol Rep       Date:  2012-12-29       Impact factor: 2.316

Review 5.  Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function.

Authors:  Matthew D Taves; Celso E Gomez-Sanchez; Kiran K Soma
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-03       Impact factor: 4.310

6.  Current Treatment Options for CHF Management: Focus on the Renin-Angiotensin-Aldosterone System.

Authors:  Olaf Hedrich; Richard D Patten; David Denofrio
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-05

Review 7.  The risks and benefits of aldosterone antagonists.

Authors:  Domenic A Sica
Journal:  Curr Heart Fail Rep       Date:  2005-08

8.  Prevention and Reversal of LV Remodeling with Neurohormonal Inhibitors.

Authors:  Richard D. Patten; Prem Soman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-08

9.  Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study.

Authors:  Xiaoying Ni; Jisheng Zhang; Ping Zhang; Fuquan Wu; Min Xia; Guanghui Ying; Jianghua Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-07-22       Impact factor: 3.738

Review 10.  Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone.

Authors:  N Muñoz-Durango; A Vecchiola; L M Gonzalez-Gomez; F Simon; C A Riedel; C E Fardella; A M Kalergis
Journal:  Biomed Res Int       Date:  2015-09-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.